Agios Pharmaceuticals, Inc.
NASDAQ:AGIO · NASDAQ Global Select
+$0.50 today
Vol 1.78M · Avg 1.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AGIO · Revenue to Net Income
Key Ratios
Analysis
$66.0M of revenue converted into -$422.6M of net income for the selected period. Gross margin is 81.0% and net margin is -680.3%, showing how much revenue survives after costs and taxes. EPS is $-7.25, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M +48.0% | $36.5M +36.1% | $26.8M +88.4% | $14.2M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $11.5M +176.6% | $4.2M -56.2% | $9.5M +457.7% | $1.7M -90.9% | $18.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $42.5M +31.5% | $32.3M +86.7% | $17.3M +38.2% | $12.5M +166.8% | -$18.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 78.7% -9.9pp | 88.6% +24.0pp | 64.6% -23.5pp | 88.0% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $334.4M +11.0% | $301.3M +4.3% | $288.9M +3.2% | $279.9M +8.9% | $257.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $180.3M +15.0% | $156.8M +30.8% | $119.9M -1.5% | $121.7M +0.2% | $121.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $514.6M +12.3% | $458.1M +12.1% | $408.8M +1.8% | $401.6M +11.7% | $359.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.2M -8.4% | $5.7M -14.6% | $6.6M -22.7% | $8.6M -54.4% | $18.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$408.6M -156.5% | $723.6M +309.5% | -$345.5M -54.8% | -$223.2M +33.9% | -$337.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -756.3% -2738.9pp | 1982.6% +3270.6pp | -1287.9% +279.7pp | -1567.7% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$472.1M -10.9% | -$425.7M -8.7% | -$391.5M -0.6% | -$389.0M -2.8% | -$378.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -873.9% +292.6pp | -1166.5% +293.1pp | -1459.5% +1272.6pp | -2732.1% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $56.4M +17.3% | $48.1M +44.2% | $33.3M +160.6% | $12.8M +1430.3% | $836.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $58.3M -94.9% | $1.1B +2802.9% | $39.4M -74.9% | $157.2M +617.8% | $21.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$413.8M -157.6% | $718.0M +303.9% | -$352.1M -51.9% | -$231.8M +35.0% | -$356.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -765.9% -2733.0pp | 1967.1% +3279.8pp | -1312.6% +315.2pp | -1627.8% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$1.0M -102.3% | $44.2M | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$412.8M -161.3% | $673.7M +291.4% | -$352.1M -51.9% | -$231.8M -114.4% | $1.6B | $4.9B | $4.8B | $4.7B |
| Net Margin | -764.0% -2609.9pp | 1845.9% +3158.6pp | -1312.6% +315.2pp | -1627.8% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$7 -160.0% | $12 +287.4% | -$6 -49.6% | -$4 +33.5% | -$6 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$7 -161.2% | $12 +283.9% | -$6 -49.6% | -$4 +33.5% | -$6 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $58.0M +2.1% | $56.8M +2.1% | $55.7M +1.6% | $54.8M -9.4% | $60.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $58.0M +0.1% | $57.9M +4.0% | $55.7M +1.6% | $54.8M -9.4% | $60.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.42B
Liquidia Corporation
NASDAQ:LQDA
$5.96B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.85B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.73B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.40B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.41B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
$1.81B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AGIO generate?
Agios Pharmaceuticals, Inc. (AGIO) reported $54.03M of revenue in fiscal 2025.
Is AGIO profitable?
Agios Pharmaceuticals, Inc. (AGIO) reported -$412,781,000.00 of net income, with a net margin of -764.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.